TCRT · Alaunos Therapeutics, Inc.
$1.84
-0.06 (-3.16%)
At close · Jul 30
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We require substantial additional financial resources to continue as a going concern and advance our Obesity and Metabolic Disorders Program; the failure to obtain it on acceptable terms would materially harm our business.”View the 10-Q filed May 15, 2026
Market Cap
$46.40M
Shares
24.42M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5000
-50%
FY2025
Net Income
-$4.18M
+10.8%
FY2025
Operating Margin
-84500%
-36380pp
FY2025
Diluted EPS
-$2.20
+24.7%
FY2025
Operating Cash Flow
-$2.87M
+42.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3000 | $5000 | $10K | $5000 | $2.92M | $398K | $146K | $146K | $146K | — | — | — | — | $200K | $1.47M | $667K | |
| $1.44M | $1.36M | $362K | $16.28M | $25.02M | $49.64M | $52.7M | $38.33M | $34.13M | $45.08M | $157.79M | $106.79M | $32.71M | $255.2M | $212.35M | $128.9M | |
| $2.71M | $2.87M | $4.46M | $12.22M | $13.14M | $27.56M | $27.67M | $19.53M | $19.92M | $14.8M | $14.38M | $17.65M | $12.17M | $103.98M | $88.32M | $68.8M | |
| — | — | — | — | — | — | — | — | — | — | $290K | $357K | $462K | $3.31M | $2.57M | $1.92M | |
| — | — | $0 | $1.27M | — | — | — | — | — | — | — | $1.7M | $1.7M | $1.7M | — | — | |
| $4.15M | $4.23M | $4.82M | $34.27M | $38.03M | $77.95M | $80.36M | $57.86M | — | — | — | — | — | — | — | — | |
| -$4.15M | -$4.23M | -$4.81M | -$34.27M | -$35.11M | -$77.55M | -$80.36M | -$57.86M | -$53.91M | -$53.49M | -$165.31M | -$120.1M | -$43.5M | -$356.91M | -$299.2M | -$197.03M | |
| — | -84500% | -48120% | -685340% | -1201.4% | -19484.67% | -55041.78% | -39628.77% | -36921.92% | — | — | — | — | -178454.5% | -20395.09% | -29539.28% | |
| — | — | — | — | — | — | — | — | — | — | -$165.02M | -$119.74M | -$43.04M | -$353.6M | -$296.62M | -$195.11M | |
| — | — | $0 | $1.92M | $3.15M | — | — | — | — | — | — | — | — | — | — | — | |
| $36K | $49K | $133K | -$873K | -$2.63M | -$1.2M | $385K | $813K | $631K | $465K | $134K | $12K | -$5000 | $4.12M | $4.7M | $4.71M | |
| — | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$4.11M | -$4.18M | -$4.68M | -$35.14M | -$37.73M | -$78.75M | -$79.98M | -$117.8M | -$53.12M | -$54.32M | -$165.3M | -$120.09M | -$31.78M | -$340.83M | -$283.72M | -$187.59M | |
| — | -83520% | -46790% | -702800% | -1291.24% | -19786.68% | -54778.08% | -80682.19% | -36381.51% | — | — | — | — | -170415.5% | -19340.42% | -28124.74% | |
| — | -$4.28M | — | — | — | -$78.75M | -$79.98M | -$117.8M | $137.25M | -$73.26M | -$172.42M | — | — | — | — | — | |
| USD/shares | — | -$2.20 | -$2.92 | -$22.00 | -$25.50 | — | -$57.00 | -$105.00 | $144.00 | — | — | — | — | — | — | — |
| USD/shares | — | -$2.20 | -$2.92 | -$22.00 | -$25.50 | — | -$57.00 | -$105.00 | $144.00 | — | — | — | — | — | — | — |
| shares | — | 1.95M | 1.6M | 1.6M | 1.45M | 1.43M | 1.4M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.2K | 572.95K | 523.64K | — |
| shares | — | 1.95M | 1.6M | 1.6M | 1.45M | 1.43M | 1.4M | 1.12M | 958.07K | 912.92K | 869.28K | 836.11K | 674.2K | 572.95K | 523.64K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2023: $12.11M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.80×
EV/EBIT
—
P/E (TTM)
—
Peer median 1.48×
Peer medians compare against the 289 similar-size Biotechnology companies (of 522 listed).